Company · CIK 0001651308 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
BeOne Medicines Ltd. · ONC
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 MForm 4 → | Sep 10, 4:49 pm EDT | Xiaodong WangDirector | 31,027 | $36.90 | $1,144,896 | 31,027 | — | 10b5-1 |
| Sep 8, 2026 SForm 4 → | Sep 10, 4:49 pm EDT | Xiaodong WangDirector | 38,287 | $349.10 | $13,366,092 | 0 | −100% | 10b5-1 |
| Sep 1, 2026 SForm 4 → | Sep 3, 5:17 pm EDT | Titus B. BallPrincipal Accounting Officer | 132 | $355.86 | $46,974 | 0 | −100% | |
| Aug 25, 2026 SForm 4 → | Aug 27, 5:12 pm EDT | Xiaobin WuPresident and COO | 280 | $380.00 | $106,400 | 0 | −100% | 10b5-1 |
| Aug 11, 2026 SForm 4 → | Aug 13, 8:54 pm EDT | Chan Henry LeeSVP, General Counsel | 2,666 | $360.00 | $959,760 | 0 | −100% | 10b5-1 |
| Aug 11, 2026 MForm 4 → | Aug 13, 8:54 pm EDT | Chan Henry LeeSVP, General Counsel | 2,666 | $191.37 | $510,190 | 2,666 | — | 10b5-1 |
| Aug 10, 2026 SForm 4 → | Aug 12, 5:53 pm EDT | John OylerChief Executive Officer, Director | 240,810 | $359.12 | $86,480,472 | 0 | −100% | 10b5-1 |
| Aug 3, 2026 SForm 4 → | Aug 5, 5:15 pm EDT | Aaron RosenbergChief Financial Officer | 1,157 | $312.72 | $361,811 | 0 | −100% | |
| Jul 30, 2026 SForm 4 → | Aug 3, 5:18 pm EDT | Chan Henry LeeSVP, General Counsel | 1,044 | $323.69 | $337,932 | 0 | −100% | |
| Jul 22, 2026 SForm 4 → | Jul 24, 4:51 pm EDT | Chan Henry LeeSVP, General Counsel | 1,669 | $325.00 | $542,425 | 0 | −100% | 10b5-1 |
| Jul 22, 2026 MForm 4 → | Jul 24, 4:51 pm EDT | Chan Henry LeeSVP, General Counsel | 1,669 | $191.58 | $319,740 | 1,669 | — | 10b5-1 |
| Jul 20, 2026 MForm 4 → | Jul 22, 5:03 pm EDT | John OylerChief Executive Officer, Director | 33,990 | $119.96 | $4,077,440 | 33,990 | — | 10b5-1 |
| Jul 20, 2026 SForm 4 → | Jul 22, 5:03 pm EDT | John OylerChief Executive Officer, Director | 109,713 | $315.28 | $34,590,855 | 0 | −100% | 10b5-1 |
| Jul 17, 2026 SForm 4 → | Jul 17, 5:36 pm EDT | John OylerChief Executive Officer, Director | 64,628 | $312.00 | $20,163,907 | 0 | −100% | 10b5-1 |
| Jul 17, 2026 MForm 4 → | Jul 17, 5:36 pm EDT | John OylerChief Executive Officer, Director | 64,628 | $119.96 | $7,752,775 | 64,628 | — | 10b5-1 |
| Jul 15, 2026 SForm 4 → | Jul 17, 5:31 pm EDT | John OylerChief Executive Officer, Director | 283,154 | $315.56 | $89,351,598 | 0 | −100% | 10b5-1 |
| Jul 15, 2026 MForm 4 → | Jul 17, 5:31 pm EDT | John OylerChief Executive Officer, Director | 283,154 | $145.28 | $41,137,996 | 166,597 | — | 10b5-1 |
| Jul 14, 2026 MForm 4 → | Jul 14, 9:26 pm EDT | John OylerChief Executive Officer, Director | 133,600 | $54.06 | $7,222,959 | 133,600 | — | 10b5-1 |
| Jul 14, 2026 SForm 4 → | Jul 14, 9:26 pm EDT | John OylerChief Executive Officer, Director | 145,861 | $305.95 | $44,626,424 | 0 | −100% | 10b5-1 |
| Jul 10, 2026 SForm 4 → | Jul 14, 9:25 pm EDT | John OylerChief Executive Officer, Director | 60,218 | $303.18 | $18,256,808 | 0 | −100% | 10b5-1 |
| Jul 10, 2026 MForm 4 → | Jul 14, 9:25 pm EDT | John OylerChief Executive Officer, Director | 60,218 | $36.90 | $2,222,044 | 48,520 | — | 10b5-1 |
| Jul 8, 2026 SForm 4 → | Jul 10, 4:44 pm EDT | Chan Henry LeeSVP, General Counsel | 664 | $302.46 | $200,833 | 0 | −100% | 10b5-1 |
| Jul 8, 2026 MForm 4 → | Jul 10, 4:44 pm EDT | Chan Henry LeeSVP, General Counsel | 664 | $191.56 | $127,196 | 664 | — | 10b5-1 |
| Jun 23, 2026 SForm 4 → | Jun 25, 5:15 pm EDT | Xiaobin WuPresident and COO | 1,292 | $276.26 | $356,927 | 0 | −100% | |
| Jun 23, 2026 SForm 4 → | Jun 25, 5:15 pm EDT | John OylerChief Executive Officer, Director | 3,410 | $273.78 | $933,592 | 0 | −100% | |
| Jun 23, 2026 SForm 4 → | Jun 25, 5:14 pm EDT | Lai WangPresident, Global Head of R&D | 1,068 | $276.74 | $295,553 | 0 | −100% | |
| Jun 16, 2026 SForm 4 → | Jun 18, 5:19 pm EDT | Xiaobin WuPresident and COO | 1,357 | $266.76 | $361,997 | 0 | −100% | |
| Jun 16, 2026 SForm 4 → | Jun 18, 5:19 pm EDT | John OylerChief Executive Officer, Director | 3,693 | $265.55 | $980,686 | 0 | −100% | |
| Jun 16, 2026 SForm 4 → | Jun 18, 5:19 pm EDT | Chan Henry LeeSVP, General Counsel | 590 | $265.98 | $156,925 | 0 | −100% | |
| Jun 16, 2026 SForm 4 → | Jun 18, 5:19 pm EDT | Lai WangPresident, Global Head of R&D | 1,169 | $265.39 | $310,236 | 0 | −100% | |
| Jun 11, 2026 SForm 4 → | Jun 15, 5:55 pm EDT | Titus B. BallPrincipal Accounting Officer | 169 | $257.20 | $43,467 | 0 | −100% | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:55 pm EDT | Titus B. BallPrincipal Accounting Officer | 31,213 | — | — | 99,645 | — | |
| Jun 11, 2026 SForm 4 → | Jun 15, 5:55 pm EDT | Lai WangPresident, Global Head of R&D | 756 | $261.00 | $197,318 | 0 | −100% | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:55 pm EDT | Lai WangPresident, Global Head of R&D | 118,625 | — | — | 1,710,085 | — | |
| Jun 11, 2026 SForm 4 → | Jun 15, 5:55 pm EDT | Aaron RosenbergChief Financial Officer | 631 | $257.74 | $162,637 | 0 | −100% | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:55 pm EDT | Aaron RosenbergChief Financial Officer | 71,175 | — | — | 397,891 | — | |
| Jun 11, 2026 SForm 4 → | Jun 15, 5:55 pm EDT | Xiaobin WuPresident and COO | 626 | $261.20 | $163,512 | 0 | −100% | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:55 pm EDT | Xiaobin WuPresident and COO | 118,625 | — | — | 1,308,161 | — | |
| Jun 11, 2026 SForm 4 → | Jun 15, 5:55 pm EDT | Chan Henry LeeSVP, General Counsel | 428 | $257.64 | $110,268 | 0 | −100% | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:55 pm EDT | Chan Henry LeeSVP, General Counsel | 45,071 | — | — | 346,554 | — | |
| Jun 11, 2026 SForm 4 → | Jun 15, 5:55 pm EDT | John OylerChief Executive Officer, Director | 1,949 | $257.24 | $501,355 | 0 | −100% | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:55 pm EDT | John OylerChief Executive Officer, Director | 177,931 | — | — | 5,697,649 | — | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:54 pm EDT | Xiaodong WangDirector | 99,892 | — | — | 4,682,493 | — | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:51 pm EDT | Olivier BrandicourtDirector | 18,980 | — | — | 46,306 | — | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:50 pm EDT | Anthony C HooperDirector | 18,980 | — | — | 83,720 | — | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:50 pm EDT | Elizabeth Fisher MooneyDirector | 18,980 | — | — | 18,980 | — | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:50 pm EDT | Margaret DuganDirector | 18,980 | — | — | 73,164 | — | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:49 pm EDT | Charles Lazelle SawyersDirector | 18,980 | — | — | 18,984 | — | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:49 pm EDT | Shalini SharpDirector | 18,980 | — | — | 38,116 | — | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:49 pm EDT | Alessandro RivaDirector | 18,980 | — | — | 73,164 | — | |
| Jun 11, 2026 AForm 4 → | Jun 15, 4:38 pm EDT | BAKER BROS. ADVISORS LP +5Director | 37,960 | — | — | 161,550 | — | |
| Jun 8, 2026 SForm 4 → | Jun 10, 5:27 pm EDT | Titus B. BallPrincipal Accounting Officer | 136 | $271.33 | $36,901 | 0 | −100% | |
| Jun 8, 2026 SForm 4 → | Jun 10, 5:26 pm EDT | Chan Henry LeeSVP, General Counsel | 871 | $270.42 | $235,539 | 0 | −100% | |
| Jun 8, 2026 SForm 4 → | Jun 10, 5:25 pm EDT | Lai WangPresident, Global Head of R&D | 1,367 | $269.38 | $368,247 | 0 | −100% | |
| Jun 8, 2026 SForm 4 → | Jun 10, 5:23 pm EDT | Xiaobin WuPresident and COO | 1,484 | $269.37 | $399,738 | 0 | −100% | |
| Jun 8, 2026 SForm 4 → | Jun 10, 5:22 pm EDT | John OylerChief Executive Officer, Director | 4,940 | $270.56 | $1,336,548 | 0 | −100% | |
| Jun 1, 2026 SForm 4 → | Jun 3, 4:10 pm EDT | Qingqing YiDirector | 235 | $279.13 | $65,596 | 0 | −100% | |
| Mar 11, 2019 MForm 4 → | Mar 11, 7:38 pm EDT | Jane HuangCMO, Hematology | 2,565 | $29.49 | $75,642 | 2,565 | — | plan? |
| Mar 7, 2019 SForm 4 → | Mar 11, 7:38 pm EDT | Jane HuangCMO, Hematology | 2,636 | $130.28 | $343,426 | 0 | −100% | plan? |
| Mar 4, 2019 SForm 4 → | Mar 6, 6:32 pm EST | John OylerChief Executive Officer, Director | 25,499 | $151.73 | $3,868,938 | 100 | −99.6% | plan? |
| Mar 1, 2019 SForm 4 → | Mar 5, 4:08 pm EST | Xiaodong WangDirector | 5,000 | $146.82 | $734,125 | 0 | −100% | plan? |
| Dec 17, 2018 SForm 4 → | Dec 19, 6:34 pm EST | Amy C. PetersonCMO, Immuno-oncology | 20,000 | $133.68 | $2,673,536 | 0 | −100% | plan? |
| Dec 17, 2018 MForm 4 → | Dec 19, 6:34 pm EST | Amy C. PetersonCMO, Immuno-oncology | 20,000 | $29.10 | $582,000 | 10,141 | — | plan? |
| Dec 10, 2018 SForm 4 → | Dec 12, 5:28 pm EST | John OylerChief Executive Officer, Director | 4,138 | $135.78 | $561,863 | 0 | −100% | plan? |
| Dec 3, 2018 SForm 4 → | Dec 4, 5:35 pm EST | Xiaodong WangDirector | 5,000 | $152.41 | $762,061 | 0 | −100% | plan? |
| Nov 27, 2018 GForm 4 → | Nov 28, 7:23 pm EST | Xiaodong WangDirector | 89,999 | — | — | 7,773,608 | — | plan? |
| Nov 26, 2018 SForm 4 → | Nov 28, 7:26 pm EST | John OylerChief Executive Officer, Director | 29,195 | $143.66 | $4,194,035 | 4,138 | −87.6% | plan? |
| Nov 26, 2018 SForm 4 → | Nov 28, 7:25 pm EST | Jane HuangCMO, Hematology | 3,000 | $139.58 | $418,750 | 0 | −100% | plan? |
| Nov 26, 2018 MForm 4 → | Nov 28, 7:25 pm EST | Jane HuangCMO, Hematology | 3,000 | $29.49 | $88,470 | 3,000 | — | plan? |
| Nov 19, 2018 GForm 4 → | Nov 21, 6:42 pm EST | Donald W. GlazerDirector | 9,414 | — | — | 4,127,526 | — | plan? |
| Nov 19, 2018 SForm 4 → | Nov 21, 6:41 pm EST | Xiaodong WangDirector | 5,000 | $124.30 | $621,490 | 0 | −100% | plan? |
| Nov 8, 2018 SForm 4 → | Nov 13, 10:20 am EST | Amy C. PetersonCMO, Immuno-oncology | 40,000 | $120.20 | $4,808,089 | 0 | −100% | plan? late |
| Nov 8, 2018 MForm 4 → | Nov 13, 10:20 am EST | Amy C. PetersonCMO, Immuno-oncology | 40,000 | $29.10 | $1,164,000 | 12,067 | — | plan? late |
| Sep 4, 2018 SForm 4 → | Sep 5, 5:15 pm EDT | Jane HuangCMO, Hematology | 2,911 | $174.60 | $508,247 | 0 | −100% | plan? |
| Aug 29, 2018 SForm 4 → | Aug 31, 4:54 pm EDT | Donald W. GlazerDirector | 2,000 | $179.00 | $358,000 | 13,384 | −13.0% | plan? |
| Aug 23, 2018 SForm 4 → | Aug 24, 4:25 pm EDT | Amy C. PetersonCMO, Immuno-oncology | 5,769 | $169.12 | $975,666 | 0 | −100% | plan? |
| Aug 13, 2018 SForm 4 → | Aug 15, 4:23 pm EDT | Xiaodong WangDirector | 3,449 | $158.77 | $547,591 | 0 | −100% | plan? |
| Aug 2, 2018 PForm 4 → | Aug 6, 5:22 pm EDT | BAKER BROS. ADVISORS LP +5Director, 10% Owner | 5,814,100 | $108.00 | $627,922,800 | 5,250,491 | — | plan? |
| Jul 16, 2018 SForm 4 → | Jul 17, 5:02 pm EDT | John OylerChief Executive Officer, Director, 10% Owner | 2,550 | $164.12 | $418,497 | 0 | −100% | plan? |
| Jun 26, 2018 AForm 4 → | Jun 28, 7:44 pm EDT | John OylerChief Executive Officer, Director, 10% Owner | 188,266 | — | — | 17,453,322 | — | plan? |
| Jun 26, 2018 AForm 4 → | Jun 28, 7:43 pm EDT | Howard LiangCFO & Chief Strategy Officer | 52,338 | — | — | 52,338 | — | plan? |
| Jun 26, 2018 AForm 4 → | Jun 28, 7:42 pm EDT | Jane HuangCMO, Hematology | 44,564 | — | — | 309,464 | — | plan? |
| Jun 26, 2018 AForm 4 → | Jun 28, 7:41 pm EDT | Amy C. PetersonCMO, Immuno-oncology | 44,564 | — | — | 269,566 | — | plan? |
| Jun 8, 2018 AGForm 4 → | Jun 28, 7:40 pm EDT | Xiaodong WangDirector | 5,094,133 | — | — | 7,973,444 | — | plan? late |
| Jun 6, 2018 AForm 4 → | Jun 8, 6:42 pm EDT | Qingqing YiDirector | 9,290 | — | — | 9,290 | — | plan? |
| Jun 6, 2018 AForm 4 → | Jun 8, 5:50 pm EDT | Timothy Yung-Cheng ChenDirector | 9,290 | — | — | 9,290 | — | plan? |
| Jun 6, 2018 AForm 4 → | Jun 8, 5:50 pm EDT | Thomas MalleyDirector | 9,290 | — | — | 9,290 | — | plan? |
| Jun 6, 2018 AForm 4 → | Jun 8, 4:05 pm EDT | BAKER BROS. ADVISORS LP +5Director, 10% Owner | 37,160 | — | — | 73,180,602 | — | plan? |
| Apr 30, 2018 AForm 4 → | May 2, 8:52 pm EDT | Xiaobin WuPresident & GM China | 1,149,899 | — | — | 1,149,899 | — | plan? |
| Apr 30, 2018 AForm 4 → | May 2, 8:46 pm EDT | John OylerChief Executive Officer, Director, 10% Owner | 574,938 | — | — | 17,265,056 | — | plan? |
| Mar 16, 2018 SForm 4 → | Mar 20, 5:02 pm EDT | Howard LiangCFO & Chief Strategy Officer | 40,000 | $160.27 | $6,410,651 | 0 | −100% | plan? |
| Mar 16, 2018 MForm 4 → | Mar 20, 5:02 pm EDT | Howard LiangCFO & Chief Strategy Officer | 35,000 | $6.50 | $227,500 | 29,128 | — | plan? |
| Feb 28, 2018 SForm 4 → | Mar 2, 6:42 pm EST | John OylerChief Executive Officer, Director, 10% Owner | 99,000 | $145.63 | $14,416,931 | 0 | −100% | plan? |
| Feb 28, 2018 SForm 4 → | Mar 2, 6:41 pm EST | Ji LiEVP and Gl. Head of Bus. Dev. | 10,000 | $146.88 | $1,468,760 | 0 | −100% | plan? |
| Feb 28, 2018 MForm 4 → | Mar 2, 6:41 pm EST | Ji LiEVP and Gl. Head of Bus. Dev. | 10,000 | $26.65 | $266,500 | 10,000 | — | plan? |
| Jan 26, 2018 AGForm 4 → | Jun 8, 5:51 pm EDT | Donald W. GlazerDirector | 220,155 | — | — | 4,336,932 | — | plan? late |
| Jan 18, 2018 PForm 4 → | Jan 22, 5:03 pm EST | BAKER BROS. ADVISORS LP +5Director, 10% Owner | 1,980,198 | $101.00 | $199,999,998 | 5,121,404 | +63.0% | plan? |
| Dec 26, 2017 SForm 4 → | Dec 28, 5:49 pm EST | John OylerChief Executive Officer, Director, 10% Owner | 20,137 | $96.46 | $1,942,515 | 99,000 | −16.9% | plan? |
| Dec 22, 2017 GForm 5 → | Feb 13, 2018, 4:25 pm EST | Xiaodong WangDirector | 36,400 | — | — | 12,879,311 | — | plan? |
| Dec 21, 2017 SForm 4 → | Dec 22, 4:43 pm EST | Jane HuangCMO, Hematology | 1,000 | $98.00 | $98,000 | 0 | −100% | plan? |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 MForm 4 → | Sep 10, 4:49 pm EDT | Xiaodong WangDirector | 403,351 | — | — | 1,210,079 | — | 10b5-1 |
| Aug 11, 2026 MForm 4 → | Aug 13, 8:54 pm EDT | Chan Henry LeeSVP, General Counsel | 34,658 | — | — | 88,582 | — | 10b5-1 |
| Jul 22, 2026 MForm 4 → | Jul 24, 4:51 pm EDT | Chan Henry LeeSVP, General Counsel | 21,697 | — | — | 98,930 | — | 10b5-1 |
| Jul 20, 2026 MForm 4 → | Jul 22, 5:03 pm EDT | John OylerChief Executive Officer, Director | 441,870 | — | — | 0 | — | 10b5-1 |
| Jul 17, 2026 MForm 4 → | Jul 17, 5:36 pm EDT | John OylerChief Executive Officer, Director | 840,164 | — | — | 441,870 | — | 10b5-1 |
| Jul 15, 2026 MForm 4 → | Jul 17, 5:31 pm EDT | John OylerChief Executive Officer, Director | 3,681,002 | — | — | 1,282,034 | — | 10b5-1 |
| Jul 14, 2026 MForm 4 → | Jul 14, 9:26 pm EDT | John OylerChief Executive Officer, Director | 1,736,800 | — | — | 462,866 | — | 10b5-1 |
| Jul 10, 2026 MForm 4 → | Jul 14, 9:25 pm EDT | John OylerChief Executive Officer, Director | 782,834 | — | — | 1,264,666 | — | 10b5-1 |
| Jul 8, 2026 MForm 4 → | Jul 10, 4:44 pm EDT | Chan Henry LeeSVP, General Counsel | 8,632 | — | — | 105,300 | — | 10b5-1 |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:55 pm EDT | Lai WangPresident, Global Head of R&D | 229,775 | — | — | 229,775 | — | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:55 pm EDT | Aaron RosenbergChief Financial Officer | 137,865 | — | — | 137,865 | — | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:55 pm EDT | Xiaobin WuPresident and COO | 229,775 | — | — | 229,775 | — | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:55 pm EDT | Chan Henry LeeSVP, General Counsel | 87,308 | — | — | 87,308 | — | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:55 pm EDT | John OylerChief Executive Officer, Director | 344,669 | — | — | 344,669 | — | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:54 pm EDT | Xiaodong WangDirector | 193,492 | — | — | 193,492 | — | |
| Mar 11, 2019 MForm 4 → | Mar 11, 7:38 pm EDT | Jane HuangCMO, Hematology | 33,345 | — | — | 1,295,155 | — | |
| Dec 17, 2018 MForm 4 → | Dec 19, 6:34 pm EST | Amy C. PetersonCMO, Immuno-oncology | 260,000 | — | — | 820,000 | — | |
| Nov 26, 2018 MForm 4 → | Nov 28, 7:25 pm EST | Jane HuangCMO, Hematology | 39,000 | — | — | 1,328,500 | — | |
| Nov 8, 2018 MForm 4 → | Nov 13, 10:20 am EST | Amy C. PetersonCMO, Immuno-oncology | 520,000 | — | — | 1,080,000 | — | late |
| Jun 26, 2018 AForm 4 → | Jun 28, 7:44 pm EDT | John OylerChief Executive Officer, Director, 10% Owner | 1,310,088 | — | — | 1,310,088 | — | |
| Jun 26, 2018 AForm 4 → | Jun 28, 7:43 pm EDT | Howard LiangCFO & Chief Strategy Officer | 364,208 | — | — | 364,208 | — | |
| Jun 26, 2018 AForm 4 → | Jun 28, 7:42 pm EDT | Jane HuangCMO, Hematology | 310,180 | — | — | 310,180 | — | |
| Jun 26, 2018 AForm 4 → | Jun 28, 7:41 pm EDT | Amy C. PetersonCMO, Immuno-oncology | 310,180 | — | — | 310,180 | — | |
| Jun 26, 2018 AForm 4 → | Jun 28, 7:40 pm EDT | Xiaodong WangDirector | 655,044 | — | — | 655,044 | — | |
| Jun 6, 2018 AForm 4 → | Jun 8, 6:42 pm EDT | Qingqing YiDirector | 17,442 | — | — | 17,442 | — | |
| Jun 6, 2018 AForm 4 → | Jun 8, 5:51 pm EDT | Donald W. GlazerDirector | 17,442 | — | — | 17,442 | — | |
| Jun 6, 2018 AForm 4 → | Jun 8, 5:50 pm EDT | Timothy Yung-Cheng ChenDirector | 17,442 | — | — | 17,442 | — | |
| Jun 6, 2018 AForm 4 → | Jun 8, 5:50 pm EDT | Thomas MalleyDirector | 17,442 | — | — | 17,442 | — | |
| Jun 6, 2018 AForm 4 → | Jun 8, 4:05 pm EDT | BAKER BROS. ADVISORS LP +5Director, 10% Owner | 34,884 | — | — | 34,884 | — | |
| Apr 30, 2018 AForm 4 → | May 2, 8:52 pm EDT | Xiaobin WuPresident & GM China | 766,599 | — | — | 766,599 | — | |
| Apr 30, 2018 AForm 4 → | May 2, 8:46 pm EDT | John OylerChief Executive Officer, Director, 10% Owner | 996,810 | — | — | 996,810 | — | |
| Apr 2, 2018 AForm 4 → | Apr 4, 4:47 pm EDT | Jingshyh S suDirector | 63,290 | — | — | 63,290 | — | |
| Mar 16, 2018 MForm 4 → | Mar 20, 5:02 pm EDT | Howard LiangCFO & Chief Strategy Officer | 455,000 | — | — | 4,445,000 | — | |
| Feb 28, 2018 MForm 4 → | Mar 2, 6:41 pm EST | Ji LiEVP and Gl. Head of Bus. Dev. | 130,000 | — | — | 2,246,000 | — | |
| Dec 21, 2017 MForm 4 → | Dec 22, 4:43 pm EST | Jane HuangCMO, Hematology | 13,000 | — | — | 1,367,500 | — | |
| Dec 13, 2017 MForm 4 → | Dec 15, 4:05 pm EST | Jane HuangCMO, Hematology | 19,500 | — | — | 1,380,500 | — | |
| Sep 27, 2017 AForm 4 → | Oct 2, 7:10 am EDT | John OylerChief Executive Officer, Director, 10% Owner | 935,000 | — | — | 935,000 | — | late |
| Sep 27, 2017 AForm 4 → | Oct 2, 6:41 am EDT | Xiaodong WangDirector | 750,000 | — | — | 750,000 | — | late |
| Jun 29, 2017 AForm 4/A → | Jun 29, 8:05 pm EDT | Howard LiangCFO & CSO | 1,250,000 | — | — | 1,250,000 | — | |
| Jun 29, 2017 AForm 4 → | Jun 29, 6:59 pm EDT | Howard LiangCFO & CSO | 1,250,000 | — | — | 1,250,000 | — | |
| Jun 27, 2017 AForm 4 → | Jun 29, 7:04 pm EDT | Amy C. PetersonCMO, Immuno-oncology | 1,016,178 | — | — | 1,016,178 | — | |
| Jun 27, 2017 AForm 4 → | Jun 29, 7:03 pm EDT | Ji LiEVP and Gl. Head of Bus. Dev. | 750,000 | — | — | 750,000 | — | |
| Jun 27, 2017 AForm 4 → | Jun 29, 6:54 pm EDT | Jane HuangCMO, Hematology | 980,465 | — | — | 980,465 | — | |
| Jun 2, 2017 AForm 4 → | Jun 6, 4:29 pm EDT | Timothy Yung-Cheng ChenDirector | 169,988 | — | — | 169,988 | — | |
| Jun 2, 2017 AForm 4 → | Jun 6, 4:18 pm EDT | Thomas MalleyDirector | 169,988 | — | — | 169,988 | — | |
| Apr 19, 2017 AForm 4 → | Apr 21, 5:05 pm EDT | Qingqing YiDirector | 199,992 | — | — | 199,992 | — | |
| Apr 19, 2017 AForm 4 → | Apr 21, 4:43 pm EDT | Donald W. GlazerDirector | 199,992 | — | — | 199,992 | — | |
| Apr 19, 2017 AForm 4 → | Apr 21, 4:42 pm EDT | Ke TangDirector | 199,992 | — | — | 199,992 | — | |
| Apr 19, 2017 AForm 4 → | Apr 21, 4:09 pm EDT | BAKER BROS. ADVISORS LP +6Director, 10% Owner | 399,984 | — | — | 399,984 | — | |
| Nov 16, 2016 AForm 4 → | Nov 18, 4:24 pm EST | John OylerChief Executive Officer, Director, 10% Owner | 2,047,500 | — | — | 2,047,500 | — | |
| Nov 16, 2016 AForm 4 → | Nov 18, 4:11 pm EST | Howard LiangCFO & CSO | 1,752,500 | — | — | 1,752,500 | — | |
| Nov 16, 2016 AForm 4 → | Nov 18, 4:10 pm EST | Xiaodong WangDirector | 1,613,430 | — | — | 1,613,430 | — | |
| Sep 2, 2016 AForm 4 → | Sep 7, 5:13 pm EDT | Jane HuangCMO, Hematology | 1,400,000 | — | — | 1,400,000 | — | |
| Aug 22, 2016 AForm 4 → | Aug 24, 6:12 pm EDT | Amy C. PetersonCMO, Immuno-oncology | 1,600,000 | — | — | 1,600,000 | — | |
| Jul 13, 2016 AForm 4 → | Jul 15, 4:34 pm EDT | Jianxin YangSr. VP, Head of Clinical Dev. | 825,000 | — | — | 825,000 | — | |
| Jul 13, 2016 AForm 4 → | Jul 15, 4:32 pm EDT | Ji LiEVP and Gl. Head of Bus. Dev. | 260,000 | — | — | 260,000 | — | |
| Jul 13, 2016 AForm 4 → | Jul 15, 4:30 pm EDT | Wendy Xiaojun YanSr. VP, Head of Reg. Affairs | 825,000 | — | — | 825,000 | — | |
| May 3, 2016 AForm 4 → | May 5, 4:36 pm EDT | Ji LiEVP and Gl. Head of Bus. Dev. | 2,376,000 | — | — | 2,376,000 | — | |
| Feb 8, 2016 CForm 4 → | Feb 10, 4:32 pm EST | Hillhouse Capital Management, Ltd.10% Owner | 30,626,779 | — | — | 0 | — | |
| Feb 8, 2016 CForm 4 → | Feb 10, 4:28 pm EST | Merck & Co., Inc. +210% Owner | 23,646,724 | — | — | 0 | — | |
| Feb 8, 2016 CXForm 4 → | Feb 9, 8:58 pm EST | John OylerCEO, Director, 10% Owner | 9,513,934 | — | — | 0 | — | |
| Feb 8, 2016 AForm 4 → | Feb 9, 8:09 pm EST | Timothy Yung-Cheng ChenDirector | 460,626 | — | — | 460,626 | — | |
| Feb 8, 2016 CForm 4 → | Feb 9, 8:07 pm EST | CB Biotech Investment Ltd +310% Owner | 19,601,138 | — | — | 0 | — | |
| Feb 8, 2016 CXForm 4 → | Feb 9, 5:38 pm EST | BAKER BROS. ADVISORS LP +6Director, 10% Owner | 80,334,757 | — | — | 0 | — |